CJC-1295

Overview

Native GHRH has an extremely short plasma half-life of approximately 7 minutes due to rapid enzymatic degradation, making it impractical for therapeutic use. CJC-1295 addresses this limitation through four strategic amino acid substitutions (tetrasubstitution) at positions 2, 8, 15, and 27 that protect the peptide from dipeptidyl peptidase IV (DPP-IV) cleavage and other proteolytic enzymes. These modifications extend the half-life to approximately 30 minutes while maintaining full biological activity at the GHRH receptor.

ℹ️ Two Forms of CJC-1295: CJC-1295 is available in two distinct forms: CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) and CJC-1295 with DAC (Drug Affinity Complex). The DAC version includes a lysine linker that binds to serum albumin, extending half-life to 6-8 days. Each form has distinct dosing protocols and pharmacokinetic profiles.

The compound underwent clinical development for conditions including adult growth hormone deficiency and HIV-associated lipodystrophy. Phase II trials demonstrated significant, dose-dependent increases in both growth hormone and IGF-1 levels, with effects lasting considerably longer than endogenous GHRH. While clinical development was eventually discontinued, the extensive human data generated provides valuable insights into CJC-1295's pharmacology.

What distinguishes CJC-1295 from exogenous growth hormone administration is its mechanism of action. Rather than replacing the body's GH production, CJC-1295 stimulates the pituitary to release its own growth hormone, preserving the natural pulsatile secretion pattern that appears important for optimal physiological effects. This approach maintains the body's feedback regulation systems, potentially offering advantages for long-term use.

CJC-1295 exerts its effects by binding to and activating GHRH receptors (GHRH-R) on somatotroph cells in the anterior pituitary gland. This receptor is a G-protein coupled receptor (GPCR) that, when activated, triggers a cascade of intracellular signaling events leading to growth hormone synthesis and release.

Research benefits

Stimulates natural growth hormone release from the pituitary

Preserves physiological pulsatile GH secretion patterns

Enhanced stability compared to native GHRH (30-60 min half-life)

DAC version provides extended duration (6-8 day half-life)

Maintains negative feedback regulation unlike exogenous GH

Synergistic effects when combined with GHRP peptides

Promotes lean body mass and improved body composition

Supports deep sleep and recovery through GH optimization

Research applications

Adult growth hormone deficiency

Active research area with published studies

Age-related GH decline and sarcopenia

Active research area with published studies

HIV-associated lipodystrophy

Active research area with published studies

Body composition optimization

Active research area with published studies

Sleep quality and architecture

Active research area with published studies

Metabolic health and insulin sensitivity

Active research area with published studies

Wound healing and tissue repair

Active research area with published studies

Bone density and skeletal health

Active research area with published studies

Research findings

CJC-1295 has been evaluated in multiple clinical studies, primarily examining the DAC-conjugated formulation for its extended duration of action. The research provides valuable human pharmacokinetic and pharmacodynamic data.

Phase II Clinical Trial Results

A pivotal study published in the Journal of Clinical Endocrinology & Metabolism (2006) examined CJC-1295 DAC in healthy adults aged 21-61 years. Key findings included:

🔑 Key Clinical Trial Findings

• Single subcutaneous doses produced dose-dependent increases in plasma GH lasting 6+ days
• Mean IGF-1 levels increased 1.5 to 3-fold above baseline
• GH AUC (area under curve) increased 2 to 10-fold depending on dose
• Effects persisted for up to 14 days after single administration
• Generally well-tolerated with injection site reactions as most common side effect

The study demonstrated that single doses of 30, 60, or 125 μg/kg produced sustained elevations in both GH and IGF-1, with the 125 μg/kg dose showing effects lasting nearly two weeks. This confirmed the extended pharmacokinetic profile enabled by the DAC bioconjugation technology.

HIV Lipodystrophy Research

CJC-1295 was evaluated in HIV patients with lipodystrophy, a metabolic condition characterized by abnormal fat distribution. Research showed:

• Significant reductions in trunk fat accumulation
• Decreased visceral adipose tissue
• Maintained lean body mass
• Improvements in metabolic parameters

These findings supported the potential use of GHRH analogs for metabolic conditions beyond simple GH deficiency.

Comparative Research: CJC-1295 vs. Other GHRH Analogs

Studies comparing CJC-1295 to other GHRH analogs like sermorelin demonstrated superior pharmacokinetic properties:

| Compound | Half-Life | Dosing Frequency | GH Response Duration |

| --- | --- | --- | --- |

| Native GHRH | ~7 minutes | Not practical | Minutes |

| Sermorelin | 10-20 minutes | 1-2x daily | 1-2 hours |

| CJC-1295 (no DAC) | ~30 minutes | 2-3x daily | 3-4 hours |

| CJC-1295 (with DAC) | 6-8 days | 1-2x weekly | 6-14 days |

| Tesamorelin | ~38 minutes | Once daily | Hours |

Body Composition Research

Research examining CJC-1295's effects on body composition showed promising results. Studies in both healthy volunteers and clinical populations demonstrated:

• Increases in lean body mass proportional to GH/IGF-1 elevation
• Reductions in body fat percentage, particularly visceral fat
• Improved nitrogen retention suggesting enhanced protein synthesis
• Enhanced lipolytic activity consistent with elevated GH

✓ Research Highlight: The ability of CJC-1295 to elevate both GH and IGF-1 while preserving pulsatile secretion patterns suggests potential advantages over exogenous GH for body composition optimization.

Dosage and administration

Dosing protocols for CJC-1295 differ significantly based on whether the DAC or non-DAC version is being used, reflecting their vastly different pharmacokinetic profiles. The following represents dosing information from research literature—not recommendations for human use.

CJC-1295 Without DAC (Mod GRF 1-29)

Due to its approximately 30-minute half-life, CJC-1295 without DAC requires more frequent administration to maintain effective GH stimulation:

| Protocol | Dose | Frequency | Timing |

| --- | --- | --- | --- |

| Conservative | 100 mcg | 2x daily | AM fasted, before bed |

| Standard | 100 mcg | 3x daily | AM, post-workout, bedtime |

| Intensive | 100-200 mcg | 3x daily | With Ipamorelin |

ℹ️ Timing Matters: For CJC-1295 without DAC, administration should occur on an empty stomach or at least 1-2 hours after eating. Elevated blood glucose and fatty acids can significantly blunt the GH response. The bedtime dose is particularly valuable as it enhances the natural nocturnal GH surge.

CJC-1295 With DAC

The extended half-life of the DAC version allows for once or twice weekly dosing:

| Protocol | Dose | Frequency | Notes |

| --- | --- | --- | --- |

| Standard | 1-2 mg | Once weekly | Provides baseline elevation |

| Moderate | 1 mg | Twice weekly | More consistent levels |

| Clinical Trial Range | 30-125 mcg/kg | Weekly | Dose-dependent response |

Reconstitution Guidelines

1

Gather Materials

Obtain bacteriostatic water, alcohol swabs, and insulin syringes (29-31 gauge).

2

Calculate Volume

For a 2mg vial, adding 2ml bacteriostatic water yields 1mg/ml (1000mcg/ml). Each 0.1ml = 100mcg.

3

Reconstitute Gently

Direct water stream against vial wall, not directly onto powder. Let dissolve—do not shake.

4

Storage

Store reconstituted solution at 2-8°C (refrigerator). Use within 3-4 weeks.

Combination Protocols with Ipamorelin

When combined with Ipamorelin (the most common research stack), protocols typically use:

• CJC-1295 without DAC: 100mcg combined with Ipamorelin 100-200mcg
• Administered 2-3 times daily in the same injection
• Synergistic effect amplifies GH release beyond either alone
• Most common timing: morning fasted, post-workout, and 30 minutes before bed

Pro Tip

The bedtime dose is considered most important by many researchers, as it amplifies the natural nocturnal GH pulse that occurs during slow-wave (deep) sleep. This pulse is responsible for much of GH's recovery and regenerative effects.

Safety and side effects

Clinical trial data for CJC-1295 demonstrated a generally favorable safety profile, though the compound never completed full Phase III development. Understanding both observed and theoretical safety considerations is essential for researchers.

Observed Side Effects in Clinical Trials

The most commonly reported adverse events in human trials included:

💉

Injection Site Reactions

Redness, swelling, or itching at injection site—typically mild and transient.

🔥

Flushing

Warmth and redness, particularly facial, occurring shortly after injection.

😵

Dizziness/Lightheadedness

Transient, typically resolving within minutes to an hour.

🤕

Headache

Reported in some subjects, usually mild and short-lived.

⚠️ Warning: In 2006, one death occurred during CJC-1295 clinical trials, leading to program suspension. Investigation attributed the death to a pre-existing cardiac condition unrelated to the peptide, but this event contributed to discontinuation of clinical development.

Potential Concerns with Elevated GH/IGF-1

Any compound that elevates growth hormone and IGF-1 carries theoretical concerns related to these hormones' effects:

• Water retention: GH can cause fluid retention and mild edema, particularly at higher doses
• Joint discomfort: Some users report carpal tunnel-like symptoms with elevated GH
• Blood glucose effects: GH has anti-insulin effects that may affect glucose regulation
• Theoretical cancer concerns: Elevated IGF-1 has been associated with increased cancer risk in epidemiological studies, though causation is not established

DAC vs. Non-DAC Safety Considerations

The different pharmacokinetic profiles of the two versions have safety implications:

| Consideration | Without DAC | With DAC |

| --- | --- | --- |

| Receptor Desensitization Risk | Lower (pulsatile) | Higher (continuous) |

| Ability to "Stop" Effects | Clears in hours | Persists 1-2 weeks |

| Dosing Precision | More control | Less flexible |

| Mimics Natural Rhythm | More closely | Less closely |

📝 Cycling Considerations: To minimize potential receptor desensitization, many research protocols incorporate cycling—for example, 5 days on/2 days off, or 8 weeks on/4 weeks off. This may be particularly important with the DAC version given its extended receptor engagement.

Contraindications and Cautions

Based on mechanism of action and GH effects, theoretical contraindications include:

• Active malignancy or history of certain cancers
• Untreated pituitary tumors
• Diabetic retinopathy
• Pregnancy and breastfeeding
• Severe cardiac conditions

Individuals with diabetes should exercise particular caution due to GH's effects on glucose metabolism. Medical supervision and monitoring are essential for any research involving human subjects.